Next, the potent dual inhibitor—namely, 3D185, which targets FGFR1-3 and colony stimulating factor 1 receptor (CSF1R)—showed promising anti-tumor effects in FGFR-dependent and macrophage-dominant cancer models [123]. Here, FGFR1 is linked to cancer.